The time-delayed release of fleroxacin, a newer fluoroquinolone, from a mixture of racemic D-L-Lactic acid is reviewed. Ten in vitro experiments for each fleroxacin concentration of 1% and 10%, were performed. Pre-formed D-L-Lactic acid, plus fleroxacin clots were preserved in sterile 1 cm diameter tubes with one ml of nutrient broth at 37 degrees C until they were fully disintegrated. Every 24 hours the tubes were sampled and replaced by standard broth volumes. Fleroxacin levels were measured by a microbiological method. The release of fleroxacin impregnated in D-L-Lactic acid clots in these two concentrations (1% and 10%) is very promising; the levels obtained over a two month period were much higher than the minimum bacterial concentration of the expected pathogens implicated in bone infections.
Download full-text PDF |
Source |
---|
Int J Clin Pharmacol Ther
June 1997
Department of Infectious Diseases, University Hospital of Vienna, Austria.
One local side-effect closely related to the use of parenteral fluoroquinolones is phlebitis. The occurrence of this phenomenon is largely thought due to the damage of endothelial cells with subsequent inflammation. In order to evaluate the effect of ciprofloxacin, fleroxacin, and ofloxacin on the viability of human umbilical venous endothelial cells (HUVEC), intracellular ATP levels were measured by a luciferin-luciferase assay.
View Article and Find Full Text PDFJ Antimicrob Chemother
November 1996
Department of Microbiological, Neurological and Orthopaedic Sciences, University of Reggio Calabria, Cantanzaro, Italy.
The way in which an antibiotic interacts with host defences could influence the clinical outcome of many infectious diseases. The impact of RO 23-9424, a novel dual-action and extended-spectrum antibiotic, was studied on several functions of human polymorphonuclear neutrophils (PMNs). A significant (P < 0.
View Article and Find Full Text PDFBull Hosp Jt Dis
November 1996
Department of Orthopaedics, LAIKO General Hospital, Athens, Greece.
The time-delayed release of fleroxacin, a newer fluoroquinolone, from a mixture of racemic D-L-Lactic acid is reviewed. Ten in vitro experiments for each fleroxacin concentration of 1% and 10%, were performed. Pre-formed D-L-Lactic acid, plus fleroxacin clots were preserved in sterile 1 cm diameter tubes with one ml of nutrient broth at 37 degrees C until they were fully disintegrated.
View Article and Find Full Text PDFAntimicrob Agents Chemother
April 1993
Division of Infectious Diseases, University Hospital, Geneva, Switzerland.
Several recent studies have shown that bacteria either grown in vitro as adherent biofilms or recovered from infected prosthetic devices have decreased susceptibilities to antimicrobial killing. To further study the microbial and environmental factors responsible for this decreased antibiotic susceptibility, we developed an in vitro model of surface-adherent Staphylococcus aureus growing on polymethylmethacrylate coverslips coated with pure fibronectin. After exponential growth for 4 h, the population of fibronectin-attached S.
View Article and Find Full Text PDFAntimicrob Agents Chemother
April 1988
Roche Research Center, Nutley, New Jersey 07110.
The uptake of quinolone antibiotics by Escherichia coli was investigated by using fleroxacin (RO 23-6240, AM 833) as a prototype compound. The uptake of fleroxacin was reduced and its MIC was increased in the presence of magnesium. Quinolones induced lipopolysaccharide release, increased cell-surface hydrophobicity and outer membrane permeability to B-lactams, and sensitized cells to lysis by detergents.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!